Hartford MidCap HLS IB (HBMCX - Free Report) a Zacks Rank #2 (Buy) seeks long-term growth of capital. HBMCX invests the majority of its assets in common stocks of mid-capitalization companies. HBMCX may invest up to 20% of its net assets in securities of foreign issuers and non-dollar securities.
This Mid Blend fund, as of the last filing, allocates their fund in three major groups; Small Growth, Large Growth and Large Value. Further, as of the last filing, GENPACT LTD, TRANSUNION and VERISIGN INC, Inc were the top holdings for HBMCX.
The Hartford MidCap HLS IB fund, managed by Hartford, carries an expense ratio of 0.96%.
HBMCX has a history of positive total returns for over 10 years. Specifically, the fund’s returns over the 1, 3, 5 year benchmarks; 1 year 19.29%, 3 year 10.55% and 5 year 16.15%. To see how this fund performed compared in its category and other #1 and #2 Ranked Mutual Funds, please click here.
HBMCX,’s performance, as of the last filing, when compared to funds in its category was in the top 15% in 1 year, top 21% over the past 3 years, and in the 8% over the past 5 years.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Hartford MidCap HLS IB (HBMCX - Free Report) a Zacks Rank #2 (Buy) seeks long-term growth of capital. HBMCX invests the majority of its assets in common stocks of mid-capitalization companies. HBMCX may invest up to 20% of its net assets in securities of foreign issuers and non-dollar securities.
This Mid Blend fund, as of the last filing, allocates their fund in three major groups; Small Growth, Large Growth and Large Value. Further, as of the last filing, GENPACT LTD, TRANSUNION and VERISIGN INC, Inc were the top holdings for HBMCX.
The Hartford MidCap HLS IB fund, managed by Hartford, carries an expense ratio of 0.96%.
HBMCX has a history of positive total returns for over 10 years. Specifically, the fund’s returns over the 1, 3, 5 year benchmarks; 1 year 19.29%, 3 year 10.55% and 5 year 16.15%. To see how this fund performed compared in its category and other #1 and #2 Ranked Mutual Funds, please click here.
HBMCX,’s performance, as of the last filing, when compared to funds in its category was in the top 15% in 1 year, top 21% over the past 3 years, and in the 8% over the past 5 years.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on HBMCX - FREE